RT Journal Article
SR Electronic
T1 Incidence Measures for Schizophrenia among Commercial Health Insurance and Medicaid Enrollees
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.24.23286405
DO 10.1101/2023.02.24.23286405
A1 Finnerty, Molly T.
A1 Khan, Atif
A1 You, Kai
A1 Wang, Rui
A1 Gu, Gyojeong
A1 Layman, Deborah
A1 Chen, Qingxian
A1 Elhadad, Noémie
A1 Joshi, Shalmali
A1 Appelbaum, Paul S.
A1 Lencz, Todd
A1 Markx, Sander
A1 Kushner, Steven A.
A1 Rzhetsky, Andrey
YR 2024
UL http://medrxiv.org/content/early/2024/02/12/2023.02.24.23286405.abstract
AB Objective To examine and compare the prevalence, incidence, and specificity and positive predictive value of incidence measures in a national commercial insurance database and a state Medicaid database, for different age groups over the life span.Methods This cross-sectional study examined the annual prevalence of schizophrenia in 2019 in two databases: a) MarketScan, a United States national commercial insurance database (N = 16,365,997), and b) New York State Medicaid program (N = 4,414,153). A subset of these individuals with 10 years of continuous insurance prior to 2019 (2009-2018) was used to assess incidence and to create a reference standard for incidence measure testing, including positive predictive value and specificity, by age group. Continuous enrollment was required for all years of study (45-day gap allowance per year, and one or more health care services annually to ensure opportunity to be diagnosed).Results The prevalence of schizophrenia in 2019 was 0.13% in MarketScan, and 2.13% in Medicaid. Prevalence was highest in MarketScan among individuals aged 21-25 years. In contrast, prevalence in Medicaid increased over the lifespan, with the peak among those 56-60 years of age. The incidence of new-onset schizophrenia in 2019 was 0.07% in MarketScan and 0.19% in Medicaid and peaked in young adulthood (26-30 years of age) in both databases (0.16% and 0.40%, respectively). Positive predictive value (PPV) for the incidence measures was higher for women than men and increased with longer lookback periods prior to the first schizophrenia diagnosis in 2019. Using a one-year lookback period, the PPV for those ≤35 years of age was 79% in MarketScan and 51% in Medicaid; a ≥95% PPV was achieved with a two-year lookback in MarketScan, and a seven-year lookback period in Medicaid. PPVs were also higher in younger age groups; in Medicaid a two-year lookback period yielded a PPV of 68% for those ≤35 years, but was 94% for those ≤20 years. Specificity was high even for the total population with one year of observation prior to the first schizophrenia diagnosis in 2019, and was higher in Medicaid (92%) than in MarketScan (80%), increasing further with longer lookback periods in both databases.Conclusions The prevalence of schizophrenia is over 10-fold higher, and the incidence two-fold higher, in the New York State Medicaid population compared to the MarketScan national commercial insurance database. Within each database, prevalence and incidence varied by sex, age, and duration of insurance. Yet despite these differences, accurate measures of incidence of new-onset schizophrenia could be constructed with high specificity and positive predictive values.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Nathan Kline Institute for Psychiatric Research IRB The University of Chicago IRBI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors